A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease - Full Text View

A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease (CONTACT)

This study is not yet open for participant recruitment.

Verified by Medivation, Inc., August 2009

First Received: August 6, 2009 No Changes Posted

Sponsors and Collaborators:	Medivation, Inc. Pfizer
Information provided by:	Medivation, Inc.
ClinicalTrials.gov Identifier:	NCT00954590

Purpose

The purpose of this study is to determine if Dimebon is safe and effective in patients with moderate to severe Alzheimer's disease.

Condition	Intervention	Phase
Moderate to Severe Alzheimer	Drug: Dimebon (latrepirdine) Drug: Placebo	Phase III

Study Type:	Interventional
Study Design:	Treatment
Official Title:	CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease

Resource links provided by NLM:

Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer's Disease

Drug Information available for: Dimebolin

Further study details as provided by Medivation, Inc.:

Arms	Assigned Interventions
Dimebon (latrepirdine): Experimental Dimebon, 20 mg orally three times daily	Drug: Dimebon (latrepirdine) 20 mg orally three times daily
Placebo: Placebo Comparator Placebo orally three times daily	Drug: Placebo Placebo orally three times daily

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00954590

Contacts

Contact: Fong Wang, MD

415-543-3470

Sponsors and Collaborators

Medivation, Inc.

Pfizer

More Information

No publications provided

Responsible Party:	Medivation, Inc. ( Lynn Seely, MD / Chief Medical Officer )
Study ID Numbers:	DIM19
Study First Received:	August 6, 2009
Last Updated:	August 6, 2009
ClinicalTrials.gov Identifier:	NCT00954590 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Alzheimer Disease
Central Nervous System Diseases
Neurodegenerative Diseases

Brain Diseases
Dementia
Cognition Disorders
Delirium

Additional relevant MeSH terms:

Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Alzheimer Disease
Central Nervous System Diseases

Neurodegenerative Diseases
Tauopathies
Brain Diseases
Dementia

ClinicalTrials.gov processed this record on September 11, 2009